JCL Roundtable: Gender differences in reduction of CVD in response to lipid-lowering drugs

Ito, 2014, Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study, J Clin Lipidol, 8, 69, 10.1016/j.jacl.2013.10.006 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials, Lancet, 385, 1397, 10.1016/S0140-6736(14)61368-4 Kostis, 2012, Meta-analysis of statin effects in women versus men, J Am Coll Cardiol, 59, 572, 10.1016/j.jacc.2011.09.067 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282 Bushnell, 2014, Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 45, 1545, 10.1161/01.str.0000442009.06663.48 Lakoski, 2007, Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as “Low Risk” Based on Framingham Risk Score. The Multi-Ethnic Study of Atherosclerosis (MESA)., Arch Intern Med, 167, 2437, 10.1001/archinte.167.22.2437 Cohen, 2012, Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users, J Clin Lipidol, 6, 208, 10.1016/j.jacl.2012.03.003 Jacobson, 2014, NLA Task Force on Statin Safety–2014 update, J Clin Lipidol, 8, S1, 10.1016/j.jacl.2014.03.003 Ridker, 2007, Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score, JAMA, 297, 611, 10.1001/jama.297.6.611